Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 3/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 9/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 3/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20545829 | 0.85 | CTSA (0.46) | FFAR1CTSA | |
| SCHEMBL20546129 | 0.84 | CTSA (0.42) | FFAR1CTSA | |
| SCHEMBL20545785 | 0.83 | FFAR1 (0.45) | FFAR1CTSA | |
| SCHEMBL17841456 | 0.82 | CTSA (0.44) | FFAR1CTSAITGB3 | |
| SCHEMBL17841455 | 0.82 | CTSA (0.44) | FFAR1CTSAITGB3 | |
| SCHEMBL28373982 | 0.80 | ATM (0.41) | HSD17B1HSD17B2FFAR1CTSAITGB3 | |
| SCHEMBL20546716 | 0.78 | CTSA (0.38) | CTSA | |
| SCHEMBL20546005 | 0.78 | CTSA (0.36) | CTSAITGB3 | |
| SCHEMBL22691188 | 0.78 | CYP26A1 (0.44) | CTSA | |
| SCHEMBL22691183 | 0.78 | CYP26A1 (0.44) | CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615514-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-110914242-B | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGB3, ITGA1, ITGB5 | HSD17B1 2006/4885HSD17B2 2347/4885FFAR1 37/4885 |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | ITGB3, ITGA1, ITGB5 | HSD17B1 2006/4885HSD17B2 2347/4885FFAR1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.